EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Safety and efficacy of linaclotide in children aged 7–17 years with irritable bowel syndrome with constipation

Carlo Di Lorenzo, Samuel Nurko, Jeffrey S Hyams, Gerardo Rodriguez-Araujo, Valentina Shakhnovich, Miguel Saps, Michael Simon

Journal of Pediatric Gastroenterology and Nutrition · 2024-03 · 78 (3) · 539-547

DOI: 10.1002/jpn3.12103 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 28.12.2023. Verfasst von Carlo Di Lorenzo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology & Hepatology & Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Peptides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: AbbVie Inc., Ironwood Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Linaclotide, a guanylate cyclase‐C agonist, was recently approved in the United States for the treatment of children 6–17 years old with functional constipation. This study evaluated the safety and efficacy of various linaclotide doses in children 7–17 years old with irritable bowel syndrome with constipation (IBS‐C).

Methods

In this 4‐week, randomized, double‐blind, placebo‐controlled, parallel‐group, Phase 2 study, children with IBS‐C were randomized to once‐daily placebo or linaclotide (Dose A: 18 or 36 µg, B: 36 or 72 µg, and C: 72 µg or 145 µg, or 290 µg); those aged 7–11 years in a 1:1:1:1 allocation based on weight (18 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Irritable Bowel SyndromePeptidesChildHumansAdolescentTreatment OutcomeConstipationAbdominal PainDouble-Blind Method

Stichwörter der Autor:innen

abdominal painbowel movementclinical trialfunctional GI diseasespediatric

Substanzen

linaclotidePeptides

Autor:innen und Institutionen

  • Department of Gastroenterology & Hepatology & Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Boston Children's Hospital, Boston, Massachusetts, USA.
  • Connecticut Children's Medical Center, Hartford, Connecticut, USA.
  • AbbVie Inc., North Chicago, Illinois, USA.
  • Ironwood Pharmaceuticals, Inc., Boston, Massachusetts, USA.
  • University of Miami, Miami, Florida, USA.

Förderung

  • AbbVie Inc.
  • Ironwood Pharmaceuticals, Inc.

Zitieren

APA

Di Lorenzo, C., Nurko, S., Hyams, J. S., Rodriguez-Araujo, G., Shakhnovich, V., Saps, M., & Simon, M. (2024). Safety and efficacy of linaclotide in children aged 7–17 years with irritable bowel syndrome with constipation. Journal of Pediatric Gastroenterology and Nutrition, 78(3), 539-547. https://doi.org/10.1002/jpn3.12103

Vancouver

Di Lorenzo C, Nurko S, Hyams JS, Rodriguez-Araujo G, Shakhnovich V, Saps M, et al. Safety and efficacy of linaclotide in children aged 7–17 years with irritable bowel syndrome with constipation. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(3):539-547. doi:10.1002/jpn3.12103

BibTeX
@article{DiLorenzo2024,
  author = {Di Lorenzo, Carlo and Nurko, Samuel and Hyams, Jeffrey S and Rodriguez-Araujo, Gerardo and Shakhnovich, Valentina and Saps, Miguel and Simon, Michael},
  title = {Safety and efficacy of linaclotide in children aged 7–17 years with irritable bowel syndrome with constipation},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  volume = {78},
  number = {3},
  pages = {539--547},
  doi = {10.1002/jpn3.12103}
}
Kostenlos starten →